Simpler Grants.gov #PAR-25-297

NIH Funding for Pre-Clinical and Early Clinical Development of Alzheimer's Drug Candidates

This opportunity from the National Institutes of Health (NIH) provides funding for the development of new drug candidates targeting Alzheimer's disease. - Government Buyer: - National Institutes of Health (NIH) - Scope of Funding: - Supports pre-clinical and early clinical (Phase I) development of novel small-molecule and biologic drugs for Alzheimer's disease - Eligible activities include: - Medicinal chemistry - Pharmacokinetics and ADMET studies - Efficacy testing in animal models - Biomarker development for target engagement - Formulation development - GMP chemical synthesis - IND-enabling studies - Initial Phase I clinical testing - Notable Requirements and Exclusions: - Excludes basic disease mechanism research, diagnostic or prevention biomarker development, non-pharmacological interventions, repurposed drugs, combination therapies, discovery activities, and stand-alone clinical trials - OEMs and Vendors: - No specific OEMs or vendors are named, as this is a research funding opportunity - Products/Services Requested: - No specific products, part numbers, or quantities are requested; the focus is on research and development activities

Description

This Notice of Funding Opportunity (NOFO) aims to provide funding for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates targeting Alzheimer's disease. The program supports activities including medicinal chemistry, pharmacokinetics, ADMET, efficacy in animal models, biomarker development, formulation, GMP chemical synthesis, IND enabling studies, and initial Phase I clinical testing. Research not responsive to this NOFO includes basic disease mechanism studies, biomarker development for diagnostics or prevention, non-pharmacological interventions, repurposed drugs, combination therapies, discovery activities, and stand-alone clinical trials.

View original listing